A U.S. District Court judge on Monday upheld Eli Lilly and Co.’s patent on the cancer drug Alimta, protecting the compound until July 2016. It was a welcome win after a difficult few months for Indianapolis-based Lilly, which is facing a wave of patent expirations in coming years.
If the manufacturer and drugmaker can come to an agreement, Rolls-Royce would lease the space formerly occupied by Eli Lilly and Co. and relocate some of its 2,500 employees to the downtown campus on South Meridian Street. Discussions are expected to last several months.
Pharmaceutical firms led by Eli Lilly are trying to eliminate a government panel aimed at controlling Medicare spending seven months after they supported the health-care overhaul that created it.
Lilly paid $90 million in 2009 to acquire the global rights to the treatment in a bid to beef up its pipeline of medications for autoimmune diseases.
Merck & Co. is betting it can succeed where Pfizer Inc. failed, with a new type of drug to combat heart disease by raising good cholesterol levels. Indianapolis-based Eli Lilly and Co. is testing a similar pill.
Eli Lilly and Co.’s $800 million acquisition of Avid Radiopharmaceuticals Inc. is the biggest step yet in the drugmaker’s attempt to add diagnostics to its product portfolio.
Moody’s Investors Service on Monday lowered the long-term ratings of Lilly one notch, to A2 from A1, citing a wave of patent expirations the drugmaker faces in coming years.
Eli Lilly said it will acquire Avid Radiopharmaceuticals, maker of an experimental agent that could help identify patients with Alzheimer’s disease. The price could climb to $800 million if the agent is commercially successful.
The Food and Drug Administration has cleared Cymbalta for musculoskeletal pain such as arthritis and chronic lower back conditions, which could mean another $500 million in annual sales for Lilly, an analyst estimates.
San Francisco-based Breast Cancer Action wanted its message, “Eli Lilly is making us sick. Tell them to stop,” posted on local billboards. But numerous sign companies refused, the group said.
After recently deciding to close a research center in Singapore, Indianapolis-based Eli Lilly and Co. has decided to open a diabetes research center in China in the second half of 2011, further ramping up the drugmaker’s presence in the world’s fastest-growing pharmaceutical market.
Indianapolis-based Eli Lilly and Co. plans to open a diabetes research center in China, the drugmaker said Tuesday, citing the high incidence of the disease there.
Without an appeal, generic drugs are now poised to wipe away most of Lilly’s $750 million in annual U.S. revenue from Gemzar.
Indiana’s life sciences industry has weathered the recession relatively well, but Eli Lilly’s struggles and tight capital markets could threaten the future.
Eli Lilly and Co. executives have said repeatedly that the company’s bulging pipeline will produce two new drugs per year, beginning in 2013. But only three times in the past six decades has Lilly been able to launch two or more new drugs in back-to-back years.
Indiana firms have dismissed more than 1,400 life science workers over the last two years. Now BioCrossroads has launched a website that aims to keep that talent in the state.
Eli Lilly and Co., under pressure to gain new products after setbacks this month with two diabetes drugs, may try to acquire its partner Amylin Pharmaceuticals Inc.
CEO John Lechleiter claims Eli Lilly and Co. isn’t interested in big acquisitions to bolster its flagging drug pipeline, but its recently devalued partner Amylin Pharmaceuticals might be the right fit, industry analysts say.
Wall Street analysts on Thursday demanded to know what new things Eli Lilly and Co. is planning since the company’s vaunted pipeline has failed to produce a drug that will boost revenue after a wave of patent expirations. The answer: Not much.
The Indianapolis-based drugmaker reported a profit of $1.3 billion in the quarter ended Sept. 30, up 38 percent compared with last year. Excluding extraordinary items from a year ago, Lilly’s profit was up 2 percent.
